Karima Oualla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karima Oualla has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Samia Arifi
6 shared publications- Nawfel Mellas
Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
5 shared publications - Zineb Benbrahim
Medical Oncology unit, Hassan II University Hospital, Fez, Morocco
5 shared publications - Lamiae Amaadour
Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco
4 shared publications Nawfel Mellas
Medical Oncology Department, Hassn II University Hospital, University Sidi Mohamed Ben Abdellah, Fes, Morocco
3 shared publicationsLamiae Amaadour
Medical Oncology Department, Hassn II University Hospital, University Sidi Mohamed Ben Abdellah, Fes, Morocco
2 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (1) , 5
B2B: Bladder Cancer Summary
The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app
- 9 February 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (1) , 5
Open AccessB2B: Bladder Cancer Summary
The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app
- Open Access
- 9 February 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (1) , 2
B2B: Kidney Cancer Summary
The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app
- 9 February 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (1) , 2
Open AccessB2B: Kidney Cancer Summary
The 7th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 45th Annual Congress of the Société Internationale d’Urologie, was held on 31 October 2025, in Edinburgh, Scotland, and transmitted live on the SIU@U Congress app
- Open Access
- 17 February 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (1) , 18
B2B: Bladder Cancer Summary
The 6th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 44th Annual Congress of the Société Internationale d’Urologie, was held on 25 October 2024, in New Delhi, India, and transmitted live on the SIU@U Congress platform
- 17 February 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (1) , 18
Open AccessB2B: Bladder Cancer Summary
The 6th Bench-to-Bedside Uro-Oncology: GU Cancers Triad Meeting, organized in conjunction with the 44th Annual Congress of the Société Internationale d’Urologie, was held on 25 October 2024, in New Delhi, India, and transmitted live on the SIU@U Congress platform
- 1 October 2023
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 32 (5) , 223-231
Immunotherapy in urothelial carcinoma of bladder : therapeutic advances in 2023
- 1 October 2023
- Published by JLE in Cahiers Santé Médecine thérapeutique
- Vol. 32 (5) , 223-231
Immunotherapy in urothelial carcinoma of bladder : therapeutic advances in 2023
- Open Access
- 1 January 2023
- Published by Pan African Medical Journal in PAMJ Clinical Medicine
- Vol. 12 (43)
Mediastinal NUT carcinoma: about a case report including immunotherapy in therapeutic management
NUT carcinoma (NC), also known as NUT midline carcinoma, is a rare, genetically defined and highly lethal undifferentiated carcinoma occurring in the midline location of the neck, head or mediastinum. We present the case of a 36-year-old Caucasian women who consulted for dyspnea, cough and night sweats. An injected scan showed a large mediastinal mass with lymph node invasion. Transbronchial biopsies confirmed the diagnosis of NUT carcinoma. The ribonucleic acid (RNA) panel molecular biological analysis concluded in the presence of a fusion transcript bromodomain-containing protein 4 (BRD4): NUTM1 (NUT Midline Carcinoma Family Member 1) consistent with the diagnosis of NUT carcinoma. A first line treatment was administered combining immunotherapy and chemotherapy. Through this case report, we will discuss the different therapeutic options and the benefit observed in terms of survival after the addition of immunotherapy.
- 1 January 2023
- Published by Pan African Medical Journal in PAMJ Clinical Medicine
- Vol. 12 (43)
Open AccessMediastinal NUT carcinoma: about a case report including immunotherapy in therapeutic management
NUT carcinoma (NC), also known as NUT midline carcinoma, is a rare, genetically defined and highly lethal undifferentiated carcinoma occurring in the midline location of the neck, head or mediastinum. We present the case of a 36-year-old Caucasian women who consulted for dyspnea, cough and night sweats. An injected scan showed a large mediastinal mass with lymph node invasion. Transbronchial biopsies confirmed the diagnosis of NUT carcinoma. The ribonucleic acid (RNA) panel molecular biological analysis concluded in the presence of a fusion transcript bromodomain-containing protein 4 (BRD4): NUTM1 (NUT Midline Carcinoma Family Member 1) consistent with the diagnosis of NUT carcinoma. A first line treatment was administered combining immunotherapy and chemotherapy. Through this case report, we will discuss the different therapeutic options and the benefit observed in terms of survival after the addition of immunotherapy.
- Open Access
- 29 October 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9921-9928
Afebrile chemotherapy-induced neutropenia: an international survey spots oncologists’ routine clinical practice versus the standard of care and the impact of COVID-19
Introduction: Afebrile chemotherapy-induced neutropenia represents a frequent clinical situation where chemotherapy protocol, patient’s comorbidities, and disease status determine the risk of infection hence the management plan. Internationally distributed, this questionnaire aims to evaluate the routine practice and the impact of the COVID-19 pandemic on afebrile chemotherapy-induced neutropenia management. Material and methods: Coordinators from Egypt, Morocco, Azerbaijan, and Russia developed a 12-item questionnaire using Google forms to explore how oncologists deal with afebrile chemotherapy-induced neutropenia. The link to the survey was available internationally through social media and to their local societies over the period from July to September 2021. Results: We received 151 responses from 4 world regions: 58.9, 9.9, 11.3, and 15.2% from the Mena area, Russia, Europe, and Asia. The responses deviated from the guideline-driven practice as G-CSF was the most chosen option for intermediate risk that was statistically different based on the academic background of the treating physician. Half of the responders ignored patients and disease risk factors in the intermediate-risk cases that trend was statistically different based on the geographical distribution. The steroid was a valid option for intermediate and low-risk as per oncologists practicing in Russia. COVID-19 pandemic positively affected the rate of prescription of G-CSF as expected. Conclusion: The disparities in the routine practice of oncologists based on their geographical and academic backgrounds highlight the need to analyze the underlying obstacles that hinder guideline-based practice like workload or lack of the proper knowledge.
- 29 October 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9921-9928
Open AccessAfebrile chemotherapy-induced neutropenia: an international survey spots oncologists’ routine clinical practice versus the standard of care and the impact of COVID-19
Introduction: Afebrile chemotherapy-induced neutropenia represents a frequent clinical situation where chemotherapy protocol, patient’s comorbidities, and disease status determine the risk of infection hence the management plan. Internationally distributed, this questionnaire aims to evaluate the routine practice and the impact of the COVID-19 pandemic on afebrile chemotherapy-induced neutropenia management. Material and methods: Coordinators from Egypt, Morocco, Azerbaijan, and Russia developed a 12-item questionnaire using Google forms to explore how oncologists deal with afebrile chemotherapy-induced neutropenia. The link to the survey was available internationally through social media and to their local societies over the period from July to September 2021. Results: We received 151 responses from 4 world regions: 58.9, 9.9, 11.3, and 15.2% from the Mena area, Russia, Europe, and Asia. The responses deviated from the guideline-driven practice as G-CSF was the most chosen option for intermediate risk that was statistically different based on the academic background of the treating physician. Half of the responders ignored patients and disease risk factors in the intermediate-risk cases that trend was statistically different based on the geographical distribution. The steroid was a valid option for intermediate and low-risk as per oncologists practicing in Russia. COVID-19 pandemic positively affected the rate of prescription of G-CSF as expected. Conclusion: The disparities in the routine practice of oncologists based on their geographical and academic backgrounds highlight the need to analyze the underlying obstacles that hinder guideline-based practice like workload or lack of the proper knowledge.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Cancer Control
- Vol. 28
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
Head and neck squamous cell carcinoma (HNSCC) is a potential curative disease at its localized stage, by the use of multimodal treatment including surgery, radiation, and chemotherapy. While the metastatic stage is considered incurable and is characterized by poor prognosis. Conventional cytotoxic chemotherapy in addition to cetuximab were the only available systemic treatment with limited efficacy and modest median overall survival barely crossing the 1 year limit. Immunotherapy with PD-1 and PD-L1 inhibitors has revolutionized the treatment of multiple cancers. Recently, Immunotherapy is being extensively explored in head and neck cancer and clinical trials have shown impressive results that allowed to immune check point inhibitors to be the new standard of care. In this article we tried to explain the rationale and mechanisms of targeting the immune system in head and neck carcinoma and to report the results from the phase III clinical trials that put the immunotherapy as a new standard of care for head and neck cancer.
- 1 January 2021
- Published by SAGE Publications in Cancer Control
- Vol. 28
Open AccessTherapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
Head and neck squamous cell carcinoma (HNSCC) is a potential curative disease at its localized stage, by the use of multimodal treatment including surgery, radiation, and chemotherapy. While the metastatic stage is considered incurable and is characterized by poor prognosis. Conventional cytotoxic chemotherapy in addition to cetuximab were the only available systemic treatment with limited efficacy and modest median overall survival barely crossing the 1 year limit. Immunotherapy with PD-1 and PD-L1 inhibitors has revolutionized the treatment of multiple cancers. Recently, Immunotherapy is being extensively explored in head and neck cancer and clinical trials have shown impressive results that allowed to immune check point inhibitors to be the new standard of care. In this article we tried to explain the rationale and mechanisms of targeting the immune system in head and neck carcinoma and to report the results from the phase III clinical trials that put the immunotherapy as a new standard of care for head and neck cancer.
- Open Access
- 31 December 2020
- Published by MedCrave Group Kft. in Journal of Cancer Prevention & Current Research
- Vol. 11 (6) , 148-152
Diffuse large cell type B breast lymphoma: case report
- 31 December 2020
- Published by MedCrave Group Kft. in Journal of Cancer Prevention & Current Research
- Vol. 11 (6) , 148-152
Open AccessDiffuse large cell type B breast lymphoma: case report
- Open Access
- 4 November 2020
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2020, 1-9
Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.
- 4 November 2020
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2020, 1-9
Open AccessImmunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.
- Open Access
- 1 July 2020
- Published by SAGE Publications in Cancer Control
- Vol. 27 (3)
How Is Morocco Reacting to COVID-19 Crisis in Anticancer Centers?
The world is facing the pandemic linked to COVID-19 virus infection that has rapidly spread worldwide, and severe complications have been reported to occur in around a third of patients. To date, there is no approved vaccine or specific therapy against COVID-19, but many trials are ongoing with some of them showing promising results. It has been shown recently that patients with cancer are at high risk of infection and they are more susceptible to develop severe events such as the necessity of invasive ventilation and death. Therefore, this crisis presents a real challenge for health systems especially in low- and middle-income countries where the health systems are already fragile such as African countries. In this article, we describe the epidemiological situation of the infection in Morocco and the different challenges in cancer centers in the era of COVID-19, in addition to various strategies that have been implemented to prevent and control the infection spread in oncological units in order to ensure the continuation of adequate cancer care.
- 1 July 2020
- Published by SAGE Publications in Cancer Control
- Vol. 27 (3)
Open AccessHow Is Morocco Reacting to COVID-19 Crisis in Anticancer Centers?
The world is facing the pandemic linked to COVID-19 virus infection that has rapidly spread worldwide, and severe complications have been reported to occur in around a third of patients. To date, there is no approved vaccine or specific therapy against COVID-19, but many trials are ongoing with some of them showing promising results. It has been shown recently that patients with cancer are at high risk of infection and they are more susceptible to develop severe events such as the necessity of invasive ventilation and death. Therefore, this crisis presents a real challenge for health systems especially in low- and middle-income countries where the health systems are already fragile such as African countries. In this article, we describe the epidemiological situation of the infection in Morocco and the different challenges in cancer centers in the era of COVID-19, in addition to various strategies that have been implemented to prevent and control the infection spread in oncological units in order to ensure the continuation of adequate cancer care.